AR069458A1 - Una composicion farmaceutica para tratar la enfermedad relacionada con obesidad que comprende conjugado de peptido insulinotropico - Google Patents

Una composicion farmaceutica para tratar la enfermedad relacionada con obesidad que comprende conjugado de peptido insulinotropico

Info

Publication number
AR069458A1
AR069458A1 ARP080105187A ARP080105187A AR069458A1 AR 069458 A1 AR069458 A1 AR 069458A1 AR P080105187 A ARP080105187 A AR P080105187A AR P080105187 A ARP080105187 A AR P080105187A AR 069458 A1 AR069458 A1 AR 069458A1
Authority
AR
Argentina
Prior art keywords
ser
glu
gly
leu
group
Prior art date
Application number
ARP080105187A
Other languages
English (en)
Inventor
Young Jin Park
Min Young Kim
Gwan Sun Lee
Dae Hae Song
Eun Hee Kang
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/947,697 external-priority patent/US20090238838A1/en
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR069458A1 publication Critical patent/AR069458A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Reivindicacion 1: Una composicion para el tratamiento de las enfermedades relacionadas con la obesidad, que comprende un conjugado de péptido insulinotropico, que se prepara uniendo un péptido insulinotropico con una region de la inmunoglobulina Fc, mediante un enlazador no peptidílico, seleccionado del grupo que consiste en SMCC (succinimidil-4-(N-maleimido-metil)ciclohexan-1carboxilato) SFB (succinimidil-4-formilbenzoato), polietilenglicol, polipropilenglicol, polivinilpirrolidona, copolímeros de etilenglicol y propilenglicol, polioles polioxietilados, alcohol polivinílico, polisacáridos, dextrano, etiléter polivinílico, polímeros biodegradables, tales como PLA (polylactic acid, ácido poliláctico) y PLGA (polylactic-glycolic acid, ácido poliláctico-glicolico), polímeros lipídicos, quitinas, ácido hialuronico y combinaciones de los mismos. Reivindicacion 2: La composicion para el tratamiento de las enfermedades relacionadas con la obesidad de acuerdo con la reivindicacion 1, en la cual el péptido insulinotropico se selecciona del grupo que consiste en: GLP-1, exendina-3, exendina-4 o agonistas de los mismos, derivados de los mismos, fragmentos de los mismos, variantes de los mismos y combinaciones de los mismos. Reivindicacion 5: Una composicion para el tratamiento de las enfermedades relacionadas con la obesidad, que comprende un conjugado de péptido insulinotropico de la siguiente formula (1):R1-X-R2-L-F, en la cual R1 se selecciona del grupo que consiste en des-amino-histidilo, dimetil-histidilo, beta-hidroxi imidazopropionilo, 4-imidazoacetilo y beta-carboxi imidazopropionilo, R2 se selecciona del grupo que consiste en -NR2, -OH y -Lys, X se selecciona del grupo que consiste en Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Al a-Pro-Pro-Pro-Ser, Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly y Ser-Asp-Gly-Thr-Phe-Thr-Ser -Asp-Leu-Ser-Y-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu- Phe-Ile-Glu-Trp-Leu-Z-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Y se selecciona del grupo que consiste en Lys, Ser y Arg, Z se selecciona del grupo que consiste en Lys, Ser y Arg; L es un enlazador no peptidílico, y F es una inmunoglobulina Fc. Reivindicacion 6: La composicion para el tratamiento de las enfermedades relacionadas con la obesidad de acuerdo con la reivindicacion 5, en la cual L se selecciona del grupo que consiste en SMCC (succinimidil-4-(N-maleimido-metil)ciclohexan-1-carboxilato, SFB (succinimidil-4-formilbenzoato), polietilenglicol, polipropilenglicol, polivinilpirrolidona, copolímeros de etilenglicol y propilenglicol, polioles polioxietilados, alcohol polivinílico, polisacáridos, dextrano, etiléter polivinílico, polímeros biodegradables, tales como PLA (ácido poliláctico) y PLGA (ácido poliláctico-glicolico), polímeros, lípidos, quitinas, ácido hialuronico y combinaciones de ellos. Reivindicacion 20: Una composicion farmacéutica para tratar enfermedades relacionadas con la obesidad, mediante el uso de la composicion de acuerdo con la reivindicacion 1, en combinacion con una seleccionada del grupo que consiste en sustancias que denotan una actividad supresora del apetito o una actividad potenciadora del metabolismo de la energía, actividad de supresion-degradacion de los lípidos, actividad de retardo del vaciado gástrico, actividad inhibidora de la proteína tirosina fosfatasa 1b (PTP, protein tyrosine phosphatase) y una actividad inhibidora de DPPIV, lo cual incluye al GLP-1 y derivados del mismo, amilina, PYY (péptido YY), leptina, colecitoquinina (CCK), oxintomodulina, antagonista de la grelina, antagonista de NPY, rimonabant, sibutramina y orlistat.
ARP080105187A 2007-11-29 2008-11-28 Una composicion farmaceutica para tratar la enfermedad relacionada con obesidad que comprende conjugado de peptido insulinotropico AR069458A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/947,697 US20090238838A1 (en) 2003-11-13 2007-11-29 Insulinotropic peptide conjugate using an immunoglobulin fc
KR1020080083194A KR101135244B1 (ko) 2007-11-29 2008-08-26 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물

Publications (1)

Publication Number Publication Date
AR069458A1 true AR069458A1 (es) 2010-01-20

Family

ID=40988127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105187A AR069458A1 (es) 2007-11-29 2008-11-28 Una composicion farmaceutica para tratar la enfermedad relacionada con obesidad que comprende conjugado de peptido insulinotropico

Country Status (22)

Country Link
EP (1) EP2227243B1 (es)
JP (1) JP5226080B2 (es)
KR (1) KR101135244B1 (es)
CN (1) CN101878036B (es)
AR (1) AR069458A1 (es)
AU (1) AU2008330315B2 (es)
BR (1) BRPI0819864A2 (es)
CA (1) CA2706627C (es)
DK (1) DK2227243T3 (es)
ES (1) ES2521497T3 (es)
HK (1) HK1150029A1 (es)
HR (1) HRP20140997T1 (es)
IL (1) IL205667A (es)
MX (1) MX2010005866A (es)
MY (1) MY155454A (es)
NZ (1) NZ585314A (es)
PL (1) PL2227243T3 (es)
PT (1) PT2227243E (es)
RU (1) RU2446816C2 (es)
TW (1) TWI403331B (es)
WO (1) WO2009069983A2 (es)
ZA (1) ZA201003796B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2692187T3 (es) * 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
KR101577734B1 (ko) * 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR101350824B1 (ko) * 2011-12-14 2014-01-13 서울대학교산학협력단 리파아제 특이적 지질-펩타이드 기질 라이브러리 및 이를 이용한 리파아제 저해제를 유효성분으로 함유하는 비만 및 지질대사 이상 관련 질환의 치료 및 예방용 약학적 조성물
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN102580087B (zh) * 2012-03-08 2013-08-21 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
MX362432B (es) * 2012-06-04 2019-01-17 Opko Biologics Ltd Variantes de oxm pegilada.
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
RU2677800C2 (ru) * 2013-02-26 2019-01-21 Ханми Фарм. Ко., Лтд. Сайт-специфичный конъюгат инсулина
JP6374412B2 (ja) * 2013-03-05 2018-08-15 ハンミ ファーム．カンパニー リミテッドＨａｎｍｉ Ｐｈａｒｍ．Ｃｏ．，Ｌｔｄ． 生理活性ポリペプチド結合体の高収率生産のための改善された製造方法
CN104086655B (zh) * 2013-04-02 2019-02-15 常州博闻迪医药科技有限公司 胰淀素样融合蛋白及其编码基因与应用
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
CN113181346A (zh) * 2018-03-09 2021-07-30 上海仁会生物制药股份有限公司 用于治疗肥胖和体重管理的glp-1组合物
KR102193211B1 (ko) * 2019-11-27 2020-12-18 (주)디앤디파마텍 비오틴 모이어티가 결합된 폴리펩티드 및 이를 포함하는 경구 투여용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TR199802789T2 (xx) * 1996-06-05 1999-03-22 Boehringer Mannheim Gmbh Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
DK1019077T4 (da) * 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
CZ306180B6 (cs) * 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
ITPD20050253A1 (it) * 2005-08-16 2007-02-17 Sit La Precisa Spa Dispositivo per il controllo multifunzionale dell'erogazione di un gas combustibile verso un apparecchio bruciatore
US20100021480A1 (en) * 2005-10-27 2010-01-28 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体

Also Published As

Publication number Publication date
EP2227243A2 (en) 2010-09-15
WO2009069983A3 (en) 2009-08-20
PT2227243E (pt) 2014-10-22
CA2706627A1 (en) 2009-06-04
MY155454A (en) 2015-10-15
JP2011505355A (ja) 2011-02-24
IL205667A0 (en) 2010-11-30
MX2010005866A (es) 2010-06-23
NZ585314A (en) 2012-10-26
ZA201003796B (en) 2011-02-23
EP2227243B1 (en) 2014-08-13
KR20090056796A (ko) 2009-06-03
CN101878036B (zh) 2014-05-14
HRP20140997T1 (hr) 2014-12-19
KR101135244B1 (ko) 2012-04-24
TWI403331B (zh) 2013-08-01
RU2446816C2 (ru) 2012-04-10
CA2706627C (en) 2014-11-18
TW200936154A (en) 2009-09-01
DK2227243T3 (da) 2014-10-06
HK1150029A1 (en) 2011-10-28
CN101878036A (zh) 2010-11-03
BRPI0819864A2 (pt) 2017-05-23
AU2008330315B2 (en) 2012-06-21
PL2227243T3 (pl) 2015-03-31
JP5226080B2 (ja) 2013-07-03
IL205667A (en) 2016-11-30
WO2009069983A2 (en) 2009-06-04
RU2010126478A (ru) 2012-01-10
EP2227243A4 (en) 2012-05-09
AU2008330315A1 (en) 2009-06-04
ES2521497T3 (es) 2014-11-12

Similar Documents

Publication Publication Date Title
AR069458A1 (es) Una composicion farmaceutica para tratar la enfermedad relacionada con obesidad que comprende conjugado de peptido insulinotropico
AR126851A2 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas
AR100695A1 (es) Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
AR091903A1 (es) Composicion para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
CL2021000901A1 (es) Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo
AR090287A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad del higado graso no alcoholico
EP3897738A1 (en) Saponin conjugates
PE20181079A1 (es) Composicion para tratar la diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
PH12016502509A1 (en) Her2 antibody-drug conjugates
AR052041A1 (es) Inmunoconjugados de anti - integrina, metodos y usos
PE20080430A1 (es) Anticuerpo antagonista para el tratamiento del cancer
DOP2012000132A (es) Composicion farmaceutica que comprende un agonista de glp-1 y metionina
NO20083573L (no) Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
AR100639A1 (es) Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
AR076147A1 (es) Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento.
ECSP055788A (es) Sistema de suministro de fármacos
AR097161A1 (es) Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
WO2018124512A3 (ko) 압타머-약물 콘쥬게이트 및 그 용도
CR10997A (es) Metodo de tratamiento de canceres
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
AR108767A2 (es) Una composición no terapéutica para suprimir la ingesta de alimentos o reducir la grasa corporal
KR20230043117A (ko) 단일 도메인 항체, 사포닌 및 이펙터 분자의 접합체, 이를 포함하는 약학적 조성물, 상기 약학적 조성물의 치료 용도

Legal Events

Date Code Title Description
FC Refusal